FDA Clears Denali's Avlayah as First Drug Engineered to Cross the Blood-Brain Barrier
By FieldPulse Editorial · March 25, 2026
Tags: FDA, Pipeline
The FDA has granted accelerated approval to Denali Therapeutics' Avlayah for Hunter syndrome, marking the first clearance of a drug specifically engineered to penetrate the blood-brain barrier.
The FDA on March 25 approved Denali Therapeutics' Avlayah (tividenofusp alfa-eknm) for the treatment of Hunter syndrome, known clinically as mucopolysaccharidosis type II (MPS II) — a decision that marks a genuine inflection point in rare disease drug development.
Avlayah is the first FDA-approved therapy explicitly engineered to cross the blood-brain barrier (BBB), a longstanding obstacle in neuroscience and rare disease medicine.
Denali achieved this by leveraging the transferrin receptor mechanism, essentially hijacking the brain's natural iron-transport pathway to ferry a therapeutic enzyme directly into brain cells.
The result is a drug capable of addressing the cognitive and neurological symptoms of Hunter syndrome that previous enzyme replacement therapies could not reach.
The approval came via the accelerated pathway, with clearance based on a surrogate biomarker endpoint: reduction of heparan sulfate levels in cerebrospinal fluid.
Heparan sulfate accumulates abnormally in MPS II patients and is associated with neurological damage.
Whether that reduction translates to meaningful cognitive benefit will need to be confirmed in post-marketing studies — a standard condition for accelerated approvals.
The timing is notable.
The FDA recently rejected a competing Hunter syndrome program — a gene therapy from Regenxbio — underscoring how difficult the MPS II space remains even as Denali succeeded.
The contrast highlights the risk profile difference between gene therapy and a precision-engineered protein that uses known biological transport mechanisms.
Hunter syndrome is an X-linked lysosomal storage disorder that affects primarily males, causing progressive physical and neurological deterioration.
Existing enzyme replacement therapies manage some systemic symptoms but have been unable to cross the BBB, leaving the neurological component largely unaddressed.
Avlayah changes that equation.
For reps working in rare disease, neurology, or pediatric specialty accounts, A.
Source: https://www.statnews.com/2026/03/25/denali-therapeutics-hunter-syndrome-rare-disease/